Literature DB >> 31032904

Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.

Klara Miriam Elfström1,2, Karin Sundström1,3, Sonia Andersson4, Zurab Bzhalava1, Agneta Carlsten Thor2, Zohra Gzoul2, Daniel Öhman2, Helena Lamin1,3, Carina Eklund1, Joakim Dillner1,3, Sven Törnberg2,5.   

Abstract

High screening participation in the population is essential for optimal prevention of cervical cancer. Offering a high-risk human papillomavirus (HPV) self-test has previously been shown to increase participation. In this randomized health services study, we evaluated four strategies with regard to participation. Women who had not attended organized cervical screening in 10 years were eligible for inclusion. This group comprised 16,437 out of 413,487 resident women ages 33-60 (<4% of the screening target group). Among these 16,437 long-term nonattenders, 8,000 women were randomized to either (i) a HPV self-sampling kit sent directly; (ii) an invitation to order a HPV self-sampling kit using a new open source eHealth web application; (iii) an invitation to call a coordinating midwife with questions and concerns; or (iv) the standard annual renewed invitation letter with prebooked appointment time (routine practice). Overall participation, by arm, was (i) 18.7%; (ii) 10.7%; (iii) 1.9%; and (iv) 1.7%. The relative risk of participation in Arm 1 was 11.0 (95% CI 7.8-15.5), 6.3 (95% CI 4.4-8.9) in Arm 2 and 1.1 (95% CI 0.7-1.7) in Arm 3, compared to Arm 4. High-risk HPV prevalence among women who returned kits in study Arms 1 and 2 was 12.2%. In total, 63 women were directly referred to colposcopy from Arms 1 and 2; of which, 43 (68.3%) attended and 17 had a high-grade cervical lesion (CIN2+) in histology (39.5%). Targeting long-term nonattending women with sending or offering the opportunity to order self-sampling kits further increased the participation in an organized screening program.
© 2019 UICC.

Entities:  

Keywords:  HPV; cervical cancer; eHealth; screening; self-sampling

Year:  2019        PMID: 31032904     DOI: 10.1002/ijc.32374

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.

Authors:  Riina Aarnio; Ellinor Östensson; Matts Olovsson; Inger Gustavsson; Ulf Gyllensten
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

2.  Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.

Authors:  Caroline Lilliecreutz; Hanna Karlsson; Anna-Clara Spetz Holm
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

3.  Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for HPV testing among women referred for colposcopy. A cross-sectional study.

Authors:  Dorthe Ørnskov; Kirsten Jochumsen; Pernille Husted Steiner; Ivan Moulun Grunnet; Annemette Wildfang Lykkebo; Marianne Waldstrøm
Journal:  BMJ Open       Date:  2021-03-05       Impact factor: 2.692

4.  Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics.

Authors:  Clare A Aitken; Sylvia Kaljouw; Albert G Siebers; Matilde Bron; Anne Morssink; Folkert J van Kemenade; Inge M C M de Kok
Journal:  Prev Med Rep       Date:  2021-02-20

5.  Implementation of a self-sampling HPV test for non-responders to cervical cancer screening in Japan: secondary analysis of the ACCESS trial.

Authors:  Misuzu Fujita; Kengo Nagashima; Minobu Shimazu; Misae Suzuki; Ichiro Tauchi; Miwa Sakuma; Setsuko Yamamoto; Hideki Hanaoka; Makio Shozu; Nobuhide Tsuruoka; Tokuzo Kasai; Akira Hata
Journal:  Sci Rep       Date:  2022-08-25       Impact factor: 4.996

6.  Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.

Authors:  Misuzu Fujita; Minobu Shimazu; Kengo Nagashima; Misae Suzuki; Ichiro Tauchi; Miwa Sakuma; Setsuko Yamamoto; Makio Shozu; Hideki Hanaoka; Nobuhide Tsuruoka; Tokuzo Kasai; Akira Hata
Journal:  BMJ Open       Date:  2022-02-03       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.